Litcius/Paper detail

Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)

Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Ioana Braicu, David Cibula, Nicoletta Colombo, Jean‐Sébastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni, Serena Giolitto, Elena Giudice, Maria Perri, Caterina Ricci, Giovanni Scambia, Domenica Lorusso

2021International Journal of Gynecological Cancer27 citationsDOI

Topics & Concepts

MedicineOvarian cancerInternal medicineOncologyChemotherapyClinical endpointRandomized controlled trialProgression-free survivalFallopian tubeClinical trialRandomizationCancerSurgeryPARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentAdvanced Breast Cancer Therapies
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) | Litcius